Close Menu

sequencing-based diagnostics

The sequencing company reported preliminary fourth quarter revenues of $27 million and said it currently has $318 million in cash and investments.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

The collaboration builds on an oligonucleotide supply agreement the partners signed in 2019 for Clear Labs' nanopore sequencing-based food safety testing.

The partners have already identified cases in the US of the novel, highly transmissible SARS-CoV-2 variant that was first reported in the UK.

Under the non-exclusive partnership, Emedgene will integrate its genome interpretation application into Illumina's TruSight software suite.

The partners will also collaborate on a study, to be peer reviewed, that will evaluate how insurance coverage of WGS affects patient care and healthcare costs.

DNA

Weill Cornell Medicine, New York-Presbyterian Hospital, and the New York Genome Center will join Illumina to sequence the genomes of thousands of patients.

The clinical next-generation sequencing instrument is Illumina's second to receive approval from China's National Medical Products Administration.

Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.

At the AMP 2020 annual meeting, the Chicago pediatric hospital described how to modernize variant calling, as new human genome assemblies are in the works.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.